Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HL-21 tablets in adults with mild to moderate COVID-19
ChiCTR2400087960Phase 2Recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Aug 2024
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of HL-21 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Change in SARS-CoV-2 viral load from baseline at each time point. Started Aug 2024; status: recruiting.
02
Drugs
HL-21
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2400087960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087960.